Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Depascale

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Diagnostics (Basel, Switzerland)|May 27, 2023
CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory MyopathiesElisabetta Zanatta, Andrea Martini, Roberto Depascale, et al.
Rheumatology (Oxford, England)|April 28, 2021
Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritisMargherita Zen, Enrico Fuzzi, Marta Loredo Martinez, et al.
Rheumatology (Oxford, England)|April 17, 2025
Unsupervised machine learning identifies distinct systemic lupus erythematosus patient endotypes with differential response to belimumabRoberto Depascale, Raffaele Da Mutten, Julius Lindblom, et al.
Frontiers in Immunology|December 15, 2025
Efficacy of anifrolumab on skin, joint and lung involvement in anti-MDA5 positive dermatomyositis: a case reportFederico Pettorossi, Laura Brischigliaro, Marisol Bracalenti, et al.
Clinical and Experimental Rheumatology|August 5, 2022
New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohortMichela Gasparotto, Sara Bindoli, Roberto Padoan, et al.
Clinical and Experimental Rheumatology|December 3, 2024
Human epididymitis protein 4 as a biomarker of interstitial lung disease in patients with idiopathic inflammatory myopathiesElisabetta Zanatta, Beatrice Moccaldi, Andrea Martini, et al.
Frontiers in Immunology|November 3, 2025
Patients with anti-SAE+ dermatomyositis display refractory and difficult-to-treat skin manifestations: case series from two Italian cohorts and review of literatureRoberto Depascale, Anna Ghirardello, Elisabetta Zanatta, et al.
Journal of Autoimmunity|May 24, 2024
Circulating extracellular vesicles and small non-coding RNAs cargo in idiopathic inflammatory myopathies reveal differences across myositis subsetsChiara Franco, Alessandra Giannella, Michela Gasparotto, et al.
Kidney International Reports|May 20, 2024
Effect of Sustained Clinical Remission on the Risk of Lupus Flares and Impaired Kidney Function in Patients With Lupus NephritisMariele Gatto, Giulia Frontini, Marta Calatroni, et al.
Kidney International Reports|May 20, 2024
Corrigendum to "Effect of Sustained Clinical Remission on the Risk of Lupus Flares and Impaired Kidney Function in Patients With Lupus Nephritis" [<i>Kidney International Reports</i> Volume 9, Issue 4, April 2024, Pages 1047-1056]Mariele Gatto, Giulia Frontini, Marta Calatroni, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Diagnostics (Basel, Switzerland)|May 27, 2023
CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory MyopathiesElisabetta Zanatta, Andrea Martini, Roberto Depascale, et al.
Rheumatology (Oxford, England)|April 28, 2021
Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritisMargherita Zen, Enrico Fuzzi, Marta Loredo Martinez, et al.
Rheumatology (Oxford, England)|April 17, 2025
Unsupervised machine learning identifies distinct systemic lupus erythematosus patient endotypes with differential response to belimumabRoberto Depascale, Raffaele Da Mutten, Julius Lindblom, et al.
Frontiers in Immunology|December 15, 2025
Efficacy of anifrolumab on skin, joint and lung involvement in anti-MDA5 positive dermatomyositis: a case reportFederico Pettorossi, Laura Brischigliaro, Marisol Bracalenti, et al.
Clinical and Experimental Rheumatology|August 5, 2022
New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohortMichela Gasparotto, Sara Bindoli, Roberto Padoan, et al.
Clinical and Experimental Rheumatology|December 3, 2024
Human epididymitis protein 4 as a biomarker of interstitial lung disease in patients with idiopathic inflammatory myopathiesElisabetta Zanatta, Beatrice Moccaldi, Andrea Martini, et al.
Frontiers in Immunology|November 3, 2025
Patients with anti-SAE+ dermatomyositis display refractory and difficult-to-treat skin manifestations: case series from two Italian cohorts and review of literatureRoberto Depascale, Anna Ghirardello, Elisabetta Zanatta, et al.
Journal of Autoimmunity|May 24, 2024
Circulating extracellular vesicles and small non-coding RNAs cargo in idiopathic inflammatory myopathies reveal differences across myositis subsetsChiara Franco, Alessandra Giannella, Michela Gasparotto, et al.
Kidney International Reports|May 20, 2024
Effect of Sustained Clinical Remission on the Risk of Lupus Flares and Impaired Kidney Function in Patients With Lupus NephritisMariele Gatto, Giulia Frontini, Marta Calatroni, et al.
Kidney International Reports|May 20, 2024
Corrigendum to "Effect of Sustained Clinical Remission on the Risk of Lupus Flares and Impaired Kidney Function in Patients With Lupus Nephritis" [<i>Kidney International Reports</i> Volume 9, Issue 4, April 2024, Pages 1047-1056]Mariele Gatto, Giulia Frontini, Marta Calatroni, et al.
Pageof 3